Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2008

01-06-2008 | Epidemiology

NSAID use and breast cancer risk in the VITAL cohort

Authors: Ann Ready, Christine M. Velicer, Anne McTiernan, Emily White

Published in: Breast Cancer Research and Treatment | Issue 3/2008

Login to get access

Abstract

Objective

We prospectively evaluated the association between average 10-year use of NSAIDs and invasive breast cancer.

Methods

Between 2000–2002, 35,323 postmenopausal women participating in the Vitamins And Lifestyle (VITAL) study provided detailed information regarding NSAID use, lifestyle and breast cancer risk factors. Using a Cox proportional hazards model, we analyzed associations between NSAID use and incident breast cancer (N = 482) ascertained through linkage to the SEER cancer registry.

Results

Use of low-dose aspirin at 4+ days/week over ten years was associated with a decreased risk of breast cancer (HR 0.65, confidence interval [CI] 0.43–0.97) versus no use, as was moderate use of other types of NSAIDs (HR 0.78, CI 0.61–0.98) for 10-yr average use up to 3 days/week. However, more frequent use of NSAIDs other than low–dose aspirin was associated with an increased risk (HR 1.26, CI 0.96–1.65), particularly frequent use of regular or extra strength aspirin (HR 1.43, CI 1.02–2.00).

Conclusions

We did not find evidence of a global protective effect of NSAID use for the development of breast cancer. However, long-term moderate use (frequent use of low doses or moderate frequency of high doses) was associated with reduced risk, while frequent use of higher dose products was associated with increased risk.
Literature
1.
Davies GL, Martin LA, Sacks N, Dowsett M (2002) Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol 13(5):669–678PubMedCrossRef
2.
Hwang D, Scollard D, Byrne J, Levine E (1998) Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cells. J Natl Cancer Inst 90(6):455–460PubMedCrossRef
3.
Abbadessa G, Spaccamiglio A, Sartori ML et al (2006) The aspirin metabolite, salicylate, inhibits 7, 12-dimethylbenz(a)anthracene-DNA adduct formation in breast cancer cells. Int J Oncol 28(5):1131–1140PubMed
4.
Masferrer JL, Leahy KM, Koki AT et al (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306–1311PubMed
5.
Diaz-Cruz ES, Shapiro CL, Bruggemeier RW (2005) Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 90(5):2563–2570PubMedCrossRef
6.
Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL (2002) Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62(3):625–631PubMed
7.
Asano TK, McLeod RS (2006) Nonsteroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database Syst Rev 2
8.
Huls G, Koornstra JJ, Kleibeuker JH (2003) Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. Lancet 362(9379):230–232PubMedCrossRef
9.
Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5(2):133–135CrossRef
10.
Harris RE, Kasbari S, Farra W (1999) Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 6:71–73PubMed
11.
Johnson TW, Anderson KE, Lazovich D, Folsom AR (2002) Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. CEBP 11:1586–1591
12.
Harris RE, Chlebowski RT, Jackson RD et al (2003) Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Res 63:6096–6101PubMed
13.
Egan KM, Stampfer MJ, Giovannuccci E, Rosner BA, Colditz GA (1996) Prospective study of regular aspirin use and the risk of breast cancer. JNCI 88(14):988–942PubMedCrossRef
14.
Marshall SF, Bernstein L, Anton-Culver H et al (2005) Nonsteroidal anti-inflammatory drugs use and breast cancer risk by stage and hormone receptor status. J NCI 97(11):805–812
15.
Jacobs EJ, Thun MJ, Connell CJ et al (2005) Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. CEBP 14(1):261–264
16.
Cook NR, Lee IM, Gaziano JM et al (2005) Low-dose aspirin in the primary prevention of cancer: The Women’s Health Study: a randomized controlled trial. JAMA 294(1):105–106CrossRef
17.
Terry MB, Gammon MD, Zhang FF et al (2004) Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291(20):2433–2440PubMedCrossRef
18.
White E, Patterson RE, Krystal AR et al (2004) VITamins And Lifestyle Cohort study: study design and characteristics of supplement users. Am J Epidemiol 159(1):83–93PubMedCrossRef
19.
Littman AJ, White E, Kristal AR, Patterson RE, Satia-About a J, Potter JD (2004) Assessment of a one-page questionnaire on long-term recreational physical activity. Epidemiology 15(1):105–113PubMedCrossRef
20.
Baron JA, Cole BF, Sandler RS et al (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348(10):891–899PubMedCrossRef
21.
Roussouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333CrossRef
Metadata
Title
NSAID use and breast cancer risk in the VITAL cohort
Authors
Ann Ready
Christine M. Velicer
Anne McTiernan
Emily White
Publication date
01-06-2008
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9665-x

Other articles of this Issue 3/2008

Breast Cancer Research and Treatment 3/2008 Go to the issue

Epidemiology

Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors

Clinical Trial

Sentinel node biopsy in patients with multiple breast cancer

Clinical Trial

Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen

Preclinical Study

Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer

Review

259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up

Epidemiology

The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits